- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-PTAFR/ PAFR monoclonal antibody
Anti-PTAFR/ PAFR antibody for FACS & in-vivo assay
Go to PTAFR/PTAFR products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T87023-Ab-1/ GM-Tg-hg-T87023-Ab-2 | Anti-Human PTAFR monoclonal antibody | Human |
| GM-Tg-rg-T87023-Ab-1/ GM-Tg-rg-T87023-Ab-2 | Anti-Rat PTAFR monoclonal antibody | Rat |
| GM-Tg-mg-T87023-Ab-1/ GM-Tg-mg-T87023-Ab-2 | Anti-Mouse PTAFR monoclonal antibody | Mouse |
| GM-Tg-cynog-T87023-Ab-1/ GM-Tg-cynog-T87023-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PTAFR monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T87023-Ab-1/ GM-Tg-felg-T87023-Ab-2 | Anti-Feline PTAFR monoclonal antibody | Feline |
| GM-Tg-cang-T87023-Ab-1/ GM-Tg-cang-T87023-Ab-2 | Anti-Canine PTAFR monoclonal antibody | Canine |
| GM-Tg-bovg-T87023-Ab-1/ GM-Tg-bovg-T87023-Ab-2 | Anti-Bovine PTAFR monoclonal antibody | Bovine |
| GM-Tg-equg-T87023-Ab-1/ GM-Tg-equg-T87023-Ab-2 | Anti-Equine PTAFR monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T87023-Ab-1/ GM-Tg-hg-T87023-Ab-2; GM-Tg-rg-T87023-Ab-1/ GM-Tg-rg-T87023-Ab-2; GM-Tg-mg-T87023-Ab-1/ GM-Tg-mg-T87023-Ab-2; GM-Tg-cynog-T87023-Ab-1/ GM-Tg-cynog-T87023-Ab-2; GM-Tg-felg-T87023-Ab-1/ GM-Tg-felg-T87023-Ab-2; GM-Tg-cang-T87023-Ab-1/ GM-Tg-cang-T87023-Ab-2; GM-Tg-bovg-T87023-Ab-1/ GM-Tg-bovg-T87023-Ab-2; GM-Tg-equg-T87023-Ab-1/ GM-Tg-equg-T87023-Ab-2 |
| Products Name | Anti-PTAFR monoclonal antibody |
| Format | mab |
| Target Name | PTAFR |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-PTAFR benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species PTAFR/ PAFR VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLP004334 | human PTAFR Lentivirus particle |
| ORF Viral Vector | pGMLP004334 | human PTAFR Lentivirus plasmid |
| ORF Viral Vector | pGMLPm003536 | mouse Ptafr Lentivirus plasmid |
| ORF Viral Vector | pGMLPm004871 | mouse Ptafr Lentivirus plasmid |
| ORF Viral Vector | vGMLPm003536 | mouse Ptafr Lentivirus particle |
| ORF Viral Vector | vGMLPm004871 | mouse Ptafr Lentivirus particle |
Target information
| Target ID | GM-T87023 |
| Target Name | PTAFR |
| Gene ID | 5724,19204,58949,716788,487336,101085906,518283,106780838 |
| Gene Symbol and Synonyms | PAF-R,PAFR,PTAFR |
| Uniprot Accession | P25105,P46002,P35366,Q9TTY5 |
| Uniprot Entry Name | PTAFR_HUMAN,PTAFR_MACMU,PTAFR_RAT,PTAFR_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000169403 |
| Target Classification | GPCR |
The target: PTAFR, gene name: PTAFR, also named as PAFR. This gene encodes a seven-transmembrane G-protein-coupled receptor for platelet-activating factor (PAF) that localizes to lipid rafts and/or caveolae in the cell membrane. PAF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) is a phospholipid that plays a significant role in oncogenic transformation, tumor growth, angiogenesis, metastasis, and pro-inflammatory processes. Binding of PAF to the PAF-receptor (PAFR) stimulates numerous signal transduction pathways including phospholipase C, D, A2, mitogen-activated protein kinases (MAPKs), and the phosphatidylinositol-calcium second messenger system. Following PAFR activation, cells become rapidly desensitized and this refractory state is dependent on PAFR phosphorylation, internalization, and down-regulation. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
